NCT02133612
Completed
Phase 2
Phase 2 Study of Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Patients With Advanced Esophageal Cancer
Overview
- Phase
- Phase 2
- Intervention
- paclitaxel; cisplatin
- Conditions
- Esophageal Cancer
- Sponsor
- Chinese Academy of Medical Sciences
- Enrollment
- 43
- Locations
- 1
- Primary Endpoint
- 3 year overall survival
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
Esophageal cancer is a highly aggressive malignancy with a poor overall outcome.
- Five year survival rate after radical esophagectomy is modest at about 40%.The patients with regional lymph node metastases have worse outcome than those without lymph node metastases.
- No standard postoperative adjuvant chemotherapy has ever been established.
Investigators
Jing Huang
M.D
Chinese Academy of Medical Sciences
Eligibility Criteria
Inclusion Criteria
- •ability to give informed consent
- •histological proof of thoracic esophageal squamous cell carcinoma with negative proximal and distal margins
- •node-positive and pathologic stage M0 .
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- •Patients were enrolled 4 to 10 weeks after surgery.
- •Adequate organ function was required in 2 weeks of registration and was defined as: serum creatinine within normal institutional limit, and creatinine clearance (CrCl) ≥60ml/minute. Aspartate aminotransferase and bilirubin\<2 times of upper normal institutional limits.
Exclusion Criteria
- •prior chemotherapy or concurrent radiation therapy before esophagectomy
- •R1 or R2 resection
- •clinically significant hearing loss or symptomatic peripheral neuropathy during initial examination
Arms & Interventions
single arm paclitaxel and cisplatin
Intervention: paclitaxel; cisplatin
Outcomes
Primary Outcomes
3 year overall survival
Time Frame: 5 year
Secondary Outcomes
- 3 year disease-free survival(5 year)
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Phase 3
Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell CarcinomaEsophageal CancerNCT02461043Chinese Academy of Medical Sciences386
Unknown
Phase 2
Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell CancerEsophageal Squamous Cell CancerNCT02016274Shen Lin70
Recruiting
Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal CancerEsophagus AdenocarcinomaEsophagus Squamous Cell CarcinomaGastroesophageal Junction AdenocarcinomaNCT04018872Dallas VA Medical Center78
Completed
Phase 2
Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal CancerEsophageal CancerNCT00160875University Health Network, Toronto54
Unknown
Phase 2
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNCT04390958Chinese Academy of Medical Sciences70